共 50 条
- [31] Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial ESC HEART FAILURE, 2022, 9 (01): : 164 - 177
- [32] Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial CIRCULATION-HEART FAILURE, 2016, 9 (03)
- [35] A comparison of heart failure patients with reduced ejection fraction in the Moravian Midlands Registry with the LCZ696 patients in the Paradigm-HF trial BIOMEDICAL PAPERS-OLOMOUC, 2024, 168 (03): : 229 - 234
- [40] Clinical Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction and With Reduced Ejection Fraction According to the Prognostic Nutritional Index: Findings From PARADIGM-HF and PARAGON-HF JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2025, 14 (01):